Fifth Third Bancorp
CTKB icon

Fifth Third Bancorp’s Cytek Biosciences CTKB Stock Holding History

Fifth Third Bancorp’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$109K Buy
24,909
+23,997
+2,631% +$113K ﹤0.01% 2872
2025
Q4 		$4.61K Buy
912
+52
+6% +$241 ﹤0.01% 2313
2025
Q3 		$2.98K Sell
860
-836
-49% -$3.14K ﹤0.01% 2416
2025
Q2 		$5.77K Buy
1,696
+859
+103% +$2.86K ﹤0.01% 2163
2025
Q1 		$3.36K Sell
837
-1,283
-61% -$6.65K ﹤0.01% 2270
2024
Q4 		$13.8K Sell
2,120
-56
-3% -$334 ﹤0.01% 1888
2024
Q3 		$12.1K Buy
2,176
+1,350
+163% +$7.66K ﹤0.01% 1935
2024
Q2 		$4.61K Buy
826
+70
+9% +$420 ﹤0.01% 2139
2024
Q1 		$5.07K Hold
756
– – ﹤0.01% 2053
2023
Q4 		$6.89K Buy
756
+627
+486% +$3.95K ﹤0.01% 2083
2023
Q3 		$712 Sell
129
-430
-77% -$3.45K ﹤0.01% 2484
2023
Q2 		$4.77K Buy
+559
New +$5.01K ﹤0.01% 2211

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fifth Third Bancorp's CTKB Position: Q1 2026 in Review

Fifth Third Bancorp increased its Cytek Biosciences (CTKB) stake by 2,631% in Q1 2026, buying an estimated $113K and bringing the position to 24,909 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

Fifth Third Bancorp first reported a position in CTKB in Q2 2023 and has held it in 12 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Fifth Third Bancorp held 24,909 shares of Cytek Biosciences worth $109K as of Q1 2026.
  • Fifth Third Bancorp bought 23,997 Cytek Biosciences shares in Q1 2026, an estimated $113K.
  • Cytek Biosciences made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q1 2026, its #2872 holding.
  • Fifth Third Bancorp first reported a position in Cytek Biosciences in Q2 2023 and has held it in 12 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Fifth Third Bancorp's 13F filing for Q1 2026, filed 1 May 2026.